share_log

Oppenheimer Initiates Coverage On Day One Biopharmaceutical With Perform Rating

Benzinga Real-time News ·  Feb 3, 2023 05:13

Oppenheimer analyst Matthew Biegler initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Perform rating.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment